Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851473 | 0.84 | HDAC1 (0.43) | P2RX7EGLN2PTPN1RORCTOP2A | |
| SCHEMBL851029 | 0.82 | MEN1 (0.45) | LTA4HFNTAFNTBEGLN2EGLN1 | |
| SCHEMBL3182559 | 0.81 | LTA4H (0.51) | LTA4HTOP2ATOP2BTP53MAPT | |
| SCHEMBL851829 | 0.78 | EGLN2 (0.50) | FNTAFNTBEGLN2MAPTS1PR2 | |
| SCHEMBL851694 | 0.77 | RAB9A (0.44) | LTA4H | |
| SCHEMBL852056 | 0.76 | PARP15 (0.44) | FNTAFNTBEGLN2MAPTEGLN1 | |
| SCHEMBL851778 | 0.75 | EGLN2 (0.52) | EGLN2PTPN1 | |
| SCHEMBL851560 | 0.73 | MRGPRX4 (0.43) | LTA4HTP53 | |
| SCHEMBL851237 | 0.73 | RAB9A (0.44) | LTA4HMAPT | |
| SCHEMBL3940115 | 0.73 | LTA4H (0.53) | LTA4HTP53MAPTSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140200225-A1 | PROTEASE INHIBITORS | ORION CORPORATION (FI) | 2014-07-17 | — | — | US | disclosed |
| US-8722930-B2 | Protease inhibitors | ORION CORPORATION (FI) | 2014-05-13 | — | — | US | disclosed |
| US-20120136002-A1 | PROTEASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-05-31 | — | — | US | disclosed |
| EP-2432556-A1 | PROTEASE INHIBITORS | Orion Corporation (FI) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133748-A1 | PROTEASE INHIBITORS | ORION CORPORATION (FI) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200225-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | LTA4H 370/4885FNTA 2355/4885FNTB 1427/4885 |
| US-20120136002-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | LTA4H 370/4885FNTA 2355/4885FNTB 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.